Videos

Tumor Treating Fields Associated With Significant Survival Benefit in Newly Diagnosed Glioblastoma

06/05/2023

Matthew Ballo, MD, West Cancer Center, Germantown, Tennessee, discusses results from a meta-analysis of comparative studies showing a significant survival benefit with tumor treating fields therapy added to standard radiochemotherapy for patients with newly diagnosed glioblastoma.

Dr Ballo presented these findings at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Source:

Ballo MT, Conlon P, Lavy-Shahaf G, et al. Real-world experience with tumor treating fields (TTFields) in newly diagnosed glioblastoma: A survival meta-analysis with systematic review. Presented at the ASCO Annual Meeting; June 2-6, 2023; Chicago, Illinois. Abstract 2059

Recent News

Conference Coverage

Lorlatinib Provides Longest Progression Free Survival Ever Seen for Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer

06/02/2024

Allison Casey

According to updated data presented at the 2024 ASCO Annual Meeting, lorlatinib has provided the longest progression-free survival ever reported among patients with advanced ALK-positive non-small cell lung cancer.

According to updated data...

06/02/2024

Oncology

Conference Coverage

Vibostolimab Coformulated With Pembrolizumab Showed Promising Activity Among Patients With dMMR Endometrial Cancer

06/02/2024

Allison Casey

The phase 2 KEYVIBE-005 study found vibostolimab coformulated with pembrolizumab had durable antitumor activity and manageable safety among patients with advanced mismatch repair deficient (dMMR) endometrial cancer.

The phase 2 KEYVIBE-005 study...

06/02/2024

Oncology

News

Cytopenias/Proliferation Define Outcomes for Patients With Primary MF and MF from Essential Thrombocythemia or PV

05/31/2024

Amber Denham

Cytopenias and/or proliferation, over JAK2 allele burden, correlate with outcomes of patients with primary myelofibrosis and with myelofibrosis from essential thrombocythemia or polycythemia vera, according to data presented at the 2024...

Cytopenias and/or proliferation,...

05/31/2024

Oncology

Conference Coverage

Inavolisib Plus Palbociclib and Fulvestrant Showed Clinical Benefit Post-Progression Among Patients With PIK3A-Mutated, HR-Positive, HER2-Negative Breast Cancer

05/31/2024

Stephanie Holland

According to updated results from the INAVO120 trial, inavolisib plus palbociclib and fulvestrant sustained clinical benefit beyond disease progression among patients with PIK3A-mutated, HR-positive, HER2-negative, locally advanced or...

According to updated results...

05/31/2024

Oncology

News

Oral Decitabine and Cedazuridine Plus Venetoclax Shows Efficacy, Safety for Older or Unfit Patients With AML

05/31/2024

By Gina Tomaine

Decitabine and cedazuridine plus venetoclax demonstrated efficacy as a fully oral regimen and was found to be safe for older or unfit patients with acute myeloid leukemia, according to a phase 2 study.

Decitabine and cedazuridine plus...

05/31/2024

Oncology

News

First-Line Sintilimab With Pegaspargase, Gemcitabine, and Oxaliplatin for Patients With Advanced Extranodal Natural Killer/T-Cell Lymphoma

05/29/2024

Amber Denham

According to results from a phase 2 trial, the combination of sintilimab with pegaspargase, gemcitabine, and oxaliplatin exhibits efficacy and safety as a frontline regimen among patients with advanced extranodal natural killer/T-cell...

According to results from a...

05/29/2024

Oncology

News

Abemaciclib Plus Nonsteroidal Aromatase Inhibitor Improved Survival Outcomes Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer

05/23/2024

Stephanie Holland

According to final overall survival results from the MONARCH 3 study, abemaciclib plus a nonsteroidal aromatase inhibitor improved overall survival and prolonged progression-free survival among patients with HR-positive, HER2-negative...

According to final overall...

05/23/2024

Oncology

News

Addition of Relatlimab to Nivolumab and Chemotherapy Did Not Improve Response Among Patients With Unresectable, Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer

05/23/2024

Stephanie Holland

According to results from the phase 2 RELATIVITY-060 study, the addition of relatlimab to nivolumab and chemotherapy did not improve objective response among patients with unresectable, locally advanced or metastatic gastric or...

According to results from the...

05/23/2024

Oncology

News

Pembrolizumab Monotherapy Shows Promise Among Patients With BCG-Unresponsive, High-Risk NMIBC With Papillary Tumors, Without Carcinoma in Situ

05/22/2024

Stephanie Holland

According to results from cohort B of the phase 2 KEYNOTE-057 trial, pembrolizumab monotherapy demonstrated promising activity with manageable toxicity among patients with Bacillus Calmette-Guerin–unresponsive, high-risk non-muscle invasive...

According to results from cohort...

05/22/2024

Oncology

News

First-Line Brentuximab Vedotin Combined With Dacarbazine or Nivolumab for Older Patients With Classical Hodgkin Lymphoma

05/20/2024

Amber Denham

According to a phase 2 study, brentuximab vedotin combined with dacarbazine or nivolumab demonstrate safety and durable efficacy as a promising treatment alternative for older patients with classical HL unfit for initial conventional...

According to a phase 2 study,...

05/20/2024

Oncology